Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study)-Reference-Cited by-同舟云学术

Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study)

Published:2024-11 Issue: Volume:211 Page:114305
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Mandalà Mario,Ferrari Andrea,Brecht Ines B.,Suijkerbuijk Karijn PM,Maschke Linda,Giannarelli Diana,Indini Alice,Ubaldi Martina,Pecci Giulia,Atkinson Victoria,Helgadottir Hildur,Chiaravalli Stefano,Benannoune Naima,Robert Caroline,Teterycz Pawel,Rutkowski Piotr,Puig Susana,Madonna Gabriele,Kebudi Rejin,Grynberg Shirly,Arantes Lidia MRB,Bien Ewa,Krawczyk Malgorzata,Pasquale Maria Debora De,Dierselhuis Miranda P.,Massi Daniela,Long Georgina V.,Ascierto Paolo Antonio,Eggermont Alexander M.M.

Funder

Horizon Europe

Publisher

Elsevier BV

Reference16 articles.

1. Age-specific incidence of melanoma in the United States;Paulson;JAMA Dermatol,2020

2. Risk factors and outcomes of melanoma in children and adolescents: a retrospective multicenter study;Hawryluk;J Am Acad Dermatol,2024

3. Melanomas in children and adolescents: clinicopathologic features and survival outcomes;El Sharouni;J Am Acad Dermatol,2023

4. Nivolumab in previously untreated melanoma without BRAF mutation;Robert;N Engl J Med,2015

5. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma;Weber;N Engl J Med,2017

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial;European Journal of Cancer;2024-09